Swine Respiratory Disease Treatment Market By Disease Type (Viral Infections, Bacterial Infections, Mixed Infections), By Treatment Type (Pharmaceuticals {Antibiotics, Antiviral Drugs, Anti-inflammatory Drugs, Bronchodilators}, Biologics {Vaccines, Immunomodulators}, Feed Additives), By Route of Administration (Oral, Injectable, Intranasal, Topical), By Animal Type (Nursery Pigs, Grower-Finisher Pigs, Sows & Gilts, Boars), By End User (Veterinary Clinics & Hospitals, Swine Farms, Animal Research Institutes, Veterinary Pharmacies, Government & Private Veterinary Programs), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles and Market Forecast, 2025 – 2035

---

Industry Outlook

The Swine Respiratory Disease Treatment Market accounted for USD 2.41 Billion in 2024 and USD 2.56 Billion in 2025 and is expected to reach USD 4.76 Billion by 2035, growing at a CAGR of around 6.38% between 2025 and 2035. Swine Respiratory Disease Treatment involves both medical care and handling to stop, detect, and cure pig infections of the respiratory system, common causes being various bacteria, viruses, and stress from the environment. Treating cattle involves the use of antibiotics, vaccines, stronger security, and attention to managing their symptoms to avert new outbreaks. Demand for SRD treatments is growing as farmers become more concerned about pork animal health, productivity, and food safety. Because more pigs are kept crowded in commercial farms, methods for fighting respiratory diseases in pigs are advancing quickly, inspiring new veterinary and farming solutions.

Industry Experts Opinion

“Using a PRRSV infection model, our goal is to advance the comprehensive understanding of the infection and response mechanism to minimize industrial damage.”

• Dr. Jun-Mo Kim, Associate Professor, Department of Animal Science and Technology, Chung-Ang University, Korea

Report Scope:

Market Dynamics

Rising global pork consumption increases the need for effective swine respiratory disease treatments.

Rising pork consumption across the globe contributes to an increase in the neurorehabilitation devices market by affecting the farming and healthcare sectors. Pig farming is expanding globally due to rising demand for pork, which increases attention to looking after the health and efficiency of the animals. When livestock are healthy, farms lose less money, support food supply chains, and help local communities and farm workers. Workers who suffer physical pain and injuries on the job and have neurological ailments might require neurorehabilitation. Along with the development of pork farming and its consumption, more resources can be used to enhance healthcare, such as introducing advanced rehabilitation tools. Economic growth leads companies to improve healthcare facilities and purchase medical devices such as systems for neurorehabilitation, to help a growing number of patients.

The popularity of rehabilitation tools in crop cultivation promotes their market by highlighting the value of rehabilitation care for neurological problems. Longer life for many people and better public health are both increasing the rate of neurological issues caused by ageing or injury, at work or elsewhere. Attention to occupational health in farming has prompted the introduction of new rehabilitation methods to aid people recovering from sickness or injuries back to work. In addition, increased attention on health around the globe is leading authorities and private companies to work on better ways to rehabilitate people. Because pork consumption plays a part in growing both the economy and healthcare, the demand for new neurorehabilitation tools is growing.

The high prevalence of diseases like PRRS and swine flu drives demand for treatment solutions.

With Porcine Reproductive and Respiratory Syndrome (PRRS) and swine flu harming pigs so often, more demand exists for effective respiratory treatments. These infections result in many difficulties, such as trouble breathing and poor growth, in pigs, so pig farmers suffer big economic losses. So, people and experts are facing greater motivation to advance and apply new methods like vaccines, antibiotics, and effective biosecurity measures. Manufacturers of pet drugs are boosting their work to make targeted and efficient products to address these conditions. With the demand growing, people invest more in research for pets. This results in new and more varied ways to help cats and dogs. Swine producers are taking steps to prevent diseases, which is leading to more use of programs to control infectious respiratory diseases. As PRRS and swine flu keep spreading, governments and international organizations are more likely to help animal health, which boosts the growth of this sector.

The effects reach farther than just animal illness, changing how we get crops and food, participate in trade, and do business in rural areas, so their solution is needed fast. Because swine flu can also infect humans, more attention is now being given to discovering it early and managing the disease better. It goes hand in hand with international efforts to care more for animals and farms wisely, by using evidence-based treatments. The regular outbreaks of PRRS and swine flu trouble pig farmers, so more people are starting to realize why it is important to deal with these diseases over time. Because of this environment, companies that focus on causing an immediate impact with their products can grow their operations. With high health concerns, especially found in heavily pig farming areas, the use of new treatments for swine respiratory diseases should keep rising among veterinarians.Top of Form

High costs of treatments can discourage adoption among small and medium-scale pig farmers.

The fact that treating diseases can be very expensive often stops medium and small farmers from using treatments. Since advanced therapies, vaccines, and equipment for diagnosis can be very expensive, they are out of reach for many farmers. Some of these farmers may decide against treatment, use low-cost and ineffective remedies, or skip using safe preventive strategies. Because of this, the disease may expand, job performance drops, and it takes a longer time for the economy to recover. Many parts of the world do not support or subsidize disease prevention, there is less incentive for proper disease management.

Small-scale farmers can experience extra obstacles such as not being able to reach veterinarians easily, not having enough funds for transportation to and from clinics, and not having sufficient storage for certain veterinary products that must be stored cool. Not being able to fix these barriers easily, plus the high cost of advanced technology, limits the use of modern solutions by many organizations. Most of the attention in rural and developing regions is placed on quickly reducing immediate costs, not on lasting health investments. Many modern treatments do not see real use, holding back the market from developing more. When the market aims to add more farmers, offering low-cost solutions, subsidies, and education events is vital to encourage farmers from all farms.

Government support and funding in emerging economies can boost market expansion.

With support and grants from the government, the Swine Respiratory Disease Treatment Market has a great chance to succeed. When Asian, Latin American, and African countries concentrate on developing their food industries, priority is given to improving animal health management with the appropriate reforms and financial support. Among the actions taken are subsidizing medicines for animals, funding the growth of veterinary knowledge, and setting up veterinary centres in rural neighbourhoods. As a result, small and medium farmers are now encouraged to follow up-to-date approaches for handling pig diseases. Because advanced solutions are available to more farmers, respiratory infections can be managed more effectively, increasing both working and financial results for farms.

Better animal health is being achieved in emerging economies through collaborations with animal health groups and NGOs that focus on food security and better farming. Due to these collaborations, training programs, information campaigns, and easy access to low-cost vaccines are put in place. When knowledge and financial hurdles are lowered, people trust veterinary drugs more and choose better respiratory disease medicine. While countries try to improve their food supply chains and match export requirements, making sure swine are healthy and safe becomes more important. Such a supporting frame allows pharmaceutical companies to extend their activities and customize new products that suit the requirements of increasing markets.

Developing new vaccines and therapeutics presents the potential for better disease control.

Developing new vaccines and therapeutics offers a significant opportunity for improving disease control in the Swine Respiratory Disease Treatment Market. Current treatment options, while effective to a degree, often struggle to address the complex and multi-pathogen nature of respiratory diseases in pigs. With ongoing scientific advancements, researchers now have the tools to create more precise, targeted, and long-lasting vaccines that can protect swine from multiple pathogens with fewer doses. These innovations can reduce the need for repeated treatments and lower the risk of antimicrobial resistance, making disease control more efficient and sustainable. Companies investing in new-generation therapeutics also have the potential to stand out in the market by offering safer, faster-acting, and easier-to-administer products.

The introduction of novel therapies can greatly benefit both large commercial farms and smaller operations by reducing disease outbreaks, improving animal welfare, and increasing productivity. As producers become more aware of the economic benefits of prevention over treatment, demand for innovative solutions is expected to rise. Governments and industry stakeholders are also supporting research and development through funding and partnerships, creating a collaborative environment for product innovation. This opens the door for pharmaceutical firms and biotech startups to develop unique solutions that address evolving disease patterns and regional challenges. By focusing on next-generation vaccines and therapeutics, the market can achieve higher levels of disease control, reduced reliance on antibiotics, and better health outcomes for swine populations across the globe.

Segment Analysis

Based on Disease Type, the Swine Respiratory Disease Treatment Market is segmented into Viral Infections, Bacterial Infections, and Mixed Infections. The Mixed Infections group is showing the biggest market share. The reason is that there is often a mix of viral and bacterial infections, which means treating these diseases needs effort from several directions. Because identifying and treating dual infections is tough for many farmers and veterinarians, an increasing number of patients are being treated with broad-spectrum drugs. The reason for this segment leading the market is that companies now need strategies that address various diseases to improve outcomes and prevent economic damage.

Based on Treatment Type, the Swine Respiratory Disease Treatment Market is segmented into Pharmaceuticals (including Antibiotics, Antiviral Drugs, Anti-inflammatory Drugs, and Bronchodilators), Biologics (including Vaccines and Immunomodulators), and Feed Additives. The current largest market share within these segments belongs to Pharmaceuticals. Antibiotics and anti-inflammatory drugs act immediately to control symptoms and fight infections, which is why the effect is noticeable so fast. Although biologics and feed additives are rising in popularity for future prevention, people still turn to pharmaceuticals for effective treatment of active infections. Because farm-raised swine need these products for healthcare, and they are easy to get, pharmaceuticals continue to dominate swine respiratory disease treatment on farms of all sizes.

Regional Analysis

The North American Swine Respiratory Disease Treatment Market is well-established due to the region’s advanced pig farming industry and stringent animal health regulations. In North America, farmers and veterinarians depend heavily on vaccines, antibiotics, and biosecurity strategies to address swine respiratory diseases. Because high productivity and good meat are important, many farmers need effective and fast treatments. Spreading awareness about antibiotic resistance leads people to use other treatments and improve how they deal with infections. Growth in the market is also due to effective vet facilities and ongoing cooperation between veterinary institutions and big pharma. The area’s commitment to green farming and caring for animals helps advance and accept new respiratory disease treatments.

The Asia-Pacific Swine Respiratory Disease Treatment Market is rapidly growing, driven by the expansion of commercial pig farming and rising demand for pork across countries like China, India, and Southeast Asia. Overall market development is aided chiefly by raising awareness of swine diseases and boosting the veterinary healthcare service structure. More and more producers are using vaccines and antimicrobial treatments to lower the losses they face because of respiratory infections. But there are still problems like changing laws between countries and affordability problems in rural places. Because of efforts by the government to boost animal health and food safety, the region has strong chances for growth. In addition, greater investments by multinational companies in introducing new advanced treatments are influencing how the medical device industry in Asia-Pacific is developing.

Competitive Landscape

Several global and regional companies are present in the Swine Respiratory Disease Treatment Market, all working to meet the need for effective treatments of swine respiratory diseases. Among many animal health providers, Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, Bayer AG, and Ceva Santé Animale sell vaccines, antibiotics, and anti-inflammatory drugs to stop Mycoplasma hyopneumoniae, PRRSV, and PCV2. Research and innovation are leading these companies to introduce fresh treatments and enhance the ones they currently have.

Many firms team up with other companies to create better services and make their products available to more customers. AROVYNTM and NUFLOR-S, recently approved by Merck Animal Health, reflect the industry’s dedication to finding better treatments. Besides, the market is seeing new players join, such as small and medium-sized businesses, who are offering affordable and inventive solutions, which is resulting in additional competition and progress in the industry.

Swine Respiratory Disease Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Recent Developments:

• In January 2024, the title of Best New Food Animal Product was given to CIRCUMVENT CML by S&P Global Animal Health. Merck & Co., Inc.’s MSD Animal Health released these findings. CIRCUMVENT CML is unique as being the only single-dose intramuscular injectable vaccine available on the market.

Report Coverage:

By Disease Type

• Viral Infections
• Bacterial Infections
• Mixed Infections

By Treatment Type

• Pharmaceuticals
  • Antibiotics
  • Antiviral Drugs
  • Anti-inflammatory Drugs
  • Bronchodilators
• Biologics
  • Vaccines
  • Immunomodulators
• Feed Additives

By Route of Administration

• Oral
• Injectable
• Intranasal
• Topical

By Animal Type

• Nursery Pigs
• Grower-Finisher Pigs
• Sows & Gilts
• Boars

By End User

• Veterinary Clinics & Hospitals
• Swine Farms
• Animal Research Institutes
• Veterinary Pharmacies
• Government & Private Veterinary Programs

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim Vetmedica, Inc.
• Elanco Animal Health
• Virbac Group
• Ceva Santé Animale
• Norbrook Laboratories Ltd.
• Vetoquinol SA
• Bimeda Holdings PLC
• Agrilabs, Inc.
• Huvepharma
• HIPRA
• Kyoritsu Seiyaku Corporation
• Ashish LifeSciences Ltd.
• Phibro Animal Health Corporation

Frequently Asked Questions (FAQs)